Skip to main content Skip to search Skip to main navigation

FDA: Launch of “Elsa” AI Tool

The U.S. Food and Drug Administration (FDA) has launched Elsa, a generative AI tool aimed at enhancing the productivity of its employees, from scientists to investigators.

Key Highlights:

  • Accelerated Rollout:
    • Launched ahead of the June 30 target
    • Delivered under budget, thanks to cross-agency collaboration
  • Secure & Private:
    • Built within a high-security GovCloud
    • Does not train on data from regulated industries
    • Keeps all information internal to the FDA
  • Early Impact:
    • Speeds up clinical protocol reviews and scientific evaluations
    • Helps identify top inspection priorities
  • Functional Capabilities:
    • Summarizes adverse events for safety reviews
    • Performs label comparisons
    • Generates code for nonclinical database development
  • Future Plans:
    • Elsa is the first step in a broader AI strategy
    • More AI tools to be integrated into FDA operations over time, such as data processing and generative-AI functions

Source:

FDA: Press Announcements


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.
Read more
Previous
Next